Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial

Journal:
The Lancet Diabetes & Endocrinology
Published:
DOI:
10.1016/s2213-8587(25)00290-6
Affiliations:
14
Authors:
16
Go to article
Institutions Authors Share
Arrowhead Pharmaceuticals, United States of America (USA)
4.000000
 0.25
Stanford University, United States of America (USA)
2.000000
 0.13
Baylor College of Medicine (BCM), United States of America (USA)
1.000000
 0.06
CHU de Québec, UL, Canada
1.000000
 0.06
University of the Witwatersrand, Johannesburg (Wits University), South Africa
1.000000
 0.06
NYU Langone Health, United States of America (USA)
1.000000
 0.06
Royal Prince Alfred Hospital (RPAH), USYD, Australia
1.000000
 0.06
Medpace, United States of America (USA)
1.000000
 0.06
Mount Sinai Heart, United States of America (USA)
1.000000
 0.06
Western University (UWO), Canada
1.000000
 0.06
ECOGENE-21 Biocluster, Canada
0.500000
 0.03
University of Montreal (UdeM), Canada
0.500000
 0.03
The University of Western Australia (UWA), Australia
0.500000
 0.03
Royal Perth Hospital, Australia
0.500000
 0.03
Interested in Cardiovascular Medicine and Haematology?